HPV Testing & Pap Test Market size is $1,542.3 in 2019, growing at a CAGR of 6.1% during the forecast period 2020-2025. The human papillomavirus (HPV) test detects the presence of human papillomavirus, a virus that can lead to the development of genital warts, abnormal cervical cells or cervical cancer. HPV is a sexually transmitted virus which is the primary reason for causing cervical cancer. Pap test checks the cervix for any cells that are not normal. The cervix is the lower part of the uterus (womb), which opens into the vagina. Abnormal cervical cells, if not found and treated can lead to cervical cancer. Approximately, 90% of deaths from cervical cancer occur in middle- to low-income countries. The growing number of cervical cancer cases results in the need for new, technically advanced, and less expensive screening programs.
By Application – Segment Analysis
In 2019, Cervical Cancer Screening segment dominated the HPV Testing & Pap Test Market in terms of revenue is estimated to grow at a CAGR of 4.3% owing towards the increasing awareness about the benefits associated with the early detection of cancer and the growing government support towards controlling the incidence rate of late-stage cervical cancer. Cervical cancer screening is done to identify precancerous lesions caused by HPV so they can be removed to prevent invasive cancers from developing. According to WHO Cervical cancer is the fourth most common cancer in women. In 2018, an estimated 5,70,000 women were diagnosed with cervical cancer worldwide and about 3,11,000 women died from the disease abetting towards the market’s growth.
Request for Sample of the Report @ https://www.industryarc.com/pdfdownload.php?id=508535
Report Price: $ 5900 (Single User License)
Geography – Segment Analysis
In 2019, the North America region dominated HPV Testing & Pap Test Market in terms of revenue with a market share of 39% owing towards the increased awareness among people about cancer and favorable government policies for reimbursement in countries in the region in the region. This growth can be attributed towards the increasing research & development initiatives and government support for the improvement of the healthcare sector. According to the American Cancer Society, in US, over 13,000 women are diagnosed with cervical cancer. In most cases cervical cancer can be prevented through early detection and treatment of abnormal cell changes that occur in the cervix years before cervical cancer develops. The increasing awareness about the health and availability of new treatment methods drives the market in this region is key factors in the growth of the HPV Testing & Pap Test market. Asia Pacific is estimated to record the fastest growth rate during the forecast period 2020-2025.
Drivers – HPV Testing & Pap Test Market
Increasing In The Prevalence Of Cancer
Increasing awareness level among people regarding the availability of various treatment options for HPV Testing & Pap Test management is anticipated to impel the demand. Rising healthcare expenditure in developing economies coupled with inclination towards opting advanced stage cancer drugs is anticipated to boost market growth. Increasing number of cervical cancer cases, growing aging population are propelling the growth of the HPV testing and Pap test market. National program on prevention and management of cancer by Government is the other major factor driving growth.
Talk to one of our sales representative about the full report by providing your details in the link below:
Challenges – HPV Testing & Pap Test Market
Cost and Time Associated with Development
High cost is associated with the treatment of cancer is hampering the market’s growth. The changes in regulatory guidelines for cervical cancer screening and HPV vaccination are restraining factors for the HPV Testing & Pap Test Market.
HPV Testing & Pap Test Industry Outlook
Product Launches was the key strategy of the players in the HPV Testing & Pap Test Industry. HPV Testing & Pap Test top 10 companies include Abbott Laboratories, Qiagen N. V., Becton, Dickinson and Company, Quest Diagnostics, Hologic Inc., Roche, Arbor Vita Corporation, Femasys Inc., Onco Health Corporation, Smith & Nephew and Seegene Inc.
In January 2020, Qiagen N. V. collaborated with Amgen, Inc. to develop tissue-based companion diagnostics for Amgen’s investigational cancer treatment AMG 510 to identify patients with cancers that have the KRAS G12C mutation.
In January 2017, Abbott Laboratories acquired St. Jude Medical, Inc., establishing the company as a leader in the medical device arena. This acquisition expanded opportunities for growth and is an important part of the company’s ongoing effort to develop a strong, diverse portfolio of devices, diagnostics, nutritionals and branded generic pharmaceuticals.
Increasing awareness amongst people for early treatment is set to propel the growth of the market.
Rising healthcare expenditure is the driving factors for the growth of HPV Testing & Pap Test market.
The increased awareness pertaining to the screening programs of cervical cancer drives the market’s growth.
Europe region is estimated to record the fastest growth rate during the forecast period.
A. Cell-Free Fetal DNA Testing Market
B. Cervical Cancer Diagnostic Market
About IndustryARC : IndustryARC primarily focuses on Cutting Edge Technologies and Newer Applications market research. Our Custom Research Services are designed to provide insights on the constant flux in the global supply-demand gap of markets. Our strong team of analysts enables us to meet the client research needs at a rapid speed, with a variety of options for your business. Any other custom requirements can be discussed with our team, drop an e-mail to email@example.com to discuss more about our consulting services.